What does rilonacept cost (and what determines the price)?
Rilonacept (Arcalyst) pricing varies widely by country and payer because the final cost depends on factors like insurance coverage, pharmacy reimbursement terms, negotiated discounts, and whether it’s billed through a specialty pharmacy or a medical benefit. The specific out-of-pocket cost a patient sees can also depend on deductible status and copays.
How much do patients typically pay out of pocket?
Out-of-pocket costs for rilonacept are not fixed. Patients who have commercial insurance may pay a copay or coinsurance, while patients without insurance may face substantially higher cash prices. Assistance programs (if available) can reduce patient costs, but eligibility rules apply.
Is there a patient assistance or copay program that lowers cost?
Many high-cost biologics have manufacturer or third-party assistance options (copay cards, patient assistance for uninsured/low-income patients, or reimbursement support). Availability and eligibility depend on the patient’s location, insurance status, and income criteria. These programs can materially change what a patient pays compared with the list price.
How does rilonacept cost compare with other IL-1 inhibitors?
Cost comparisons depend on the specific comparator (for example, anakinra, canakinumab) and each product’s coverage and reimbursement. Even if two drugs have similar clinical goals, the total cost to a payer can differ due to dosing schedules, package sizes, and billing pathways (pharmacy vs medical benefit).
Where can you check the most accurate current price?
For the most reliable current number, check:
1) Your insurer’s formulary/pricing tool (best for what you’ll actually pay)
2) Your pharmacy or specialty pharmacy (they can quote based on your insurance)
3) Manufacturer or program pages (if they publish copay/assistance terms for your country)
If you tell me your country (and whether you have insurance), I can narrow down what “cost” usually means for patients there (cash price vs copay estimate).